Neuroserpin : a potential biomarker for early-onset severe preeclampsia.

Abstract

Preeclampsia is a hypertensive disease of pregnancy associated with intense inflammatory and pro-coagulant

responses. Neuroserpin is a serine protease inhibitor that has been involved in neurological and immune pro- cesses and has not yet been investigated in preeclampsia. Herein, we evaluated neuroserpin levels in association

with other inflammatory mediators (IL-17A, IL-33, and CXCL-16) during severe preeclampsia. The mediators’

plasma levels were measured by immunoassays in 24 pregnant women with severe preeclampsia (early pre- eclampsia: N = 17, late preeclampsia: N = 7), 34 normotensive pregnant women, and 32 non-pregnant women.

In general, pregnancy was associated with higher levels of neuroserpin, IL-17A, IL-33, and CXCL-16 than the non- pregnant state. However, this increase was attenuated in pregnancies complicated by severe preeclampsia.

Although neuroserpin levels did not differ between normotensive pregnant women and pregnant women with severe preeclampsia, neuroserpin levels tended to be lower in early-onset than in late-onset severe preeclampsia. There were positive correlations between neuroserpin and IL-17A, neuroserpin and CXCL-16, and IL-17A and

CXCL-16 levels in women with severe preeclampsia. In addition, although the risk for developing severe pre- eclampsia was higher in older women in this study, maternal age did not significantly influence the mediators’

levels, nor their correlations in the preeclampsia group. In summary, our data suggest that neuroserpin might be a potential biomarker for early-onset severe preeclampsia and, that the imbalance among neuroserpin, IL-17A, IL-33, and CXCL-16 levels may be associated with the pathogenesis of preeclampsia, regardless of the maternal age.